Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in relapsed/refractory multiple myeloma
NCT06235229Phase 2Recruiting
- Sponsor
- Gracell Biotechnologies
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in multiple myeloma (MM), sponsored by Gracell Biotechnologies. Started Dec 2023; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06235229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235229.